checkAd
    Startseite > Aktien > ENTERA BIO > Nachrichten
    ENTERA BIO Aktie
    2,1900
     
    EUR
    +0,46 %
    +0,0100 EUR
    Letzter Kurs 20:31:47 Lang & Schwarz
    2,1600
     
    EUR
    278 STK
    Geldkurs 20:31:47
    2,2200
     
    EUR
    278 STK
    Briefkurs 20:31:47
    ISIN: IL0011429839 · WKN: A2JQXP · Israel

    Neueste Nachrichten

    Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
    08.04.24 · globenewswire · ENTERA BIO
    Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months
    26.03.24 · globenewswire · ENTERA BIO
    Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome
    20.03.24 · globenewswire · ENTERA BIO
    Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates
    08.03.24 · globenewswire · ENTERA BIO
    Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement
    04.03.24 · globenewswire · ENTERA BIO
    Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
    30.01.24 · globenewswire · ENTERA BIO
    Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule
    03.01.24 · globenewswire · ENTERA BIO
    Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025
    26.12.23 · globenewswire · ENTERA BIO
    Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera’s Next Generation Oral Peptide Platform
    29.11.23 · globenewswire · ENTERA BIO
    Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development
    14.11.23 · globenewswire · ENTERA BIO
    Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis
    09.11.23 · globenewswire · ENTERA BIO
    Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting
    16.10.23 · globenewswire · ENTERA BIO